UA96980C2 - Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки - Google Patents

Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки

Info

Publication number
UA96980C2
UA96980C2 UAA200909229A UAA200909229A UA96980C2 UA 96980 C2 UA96980 C2 UA 96980C2 UA A200909229 A UAA200909229 A UA A200909229A UA A200909229 A UAA200909229 A UA A200909229A UA 96980 C2 UA96980 C2 UA 96980C2
Authority
UA
Ukraine
Prior art keywords
mucosal
injury
deterioration
damage
amount
Prior art date
Application number
UAA200909229A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Израэль Риос
Синтия Татхилл
Original Assignee
Сайклон Фармасютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклон Фармасютикалс, Инк. filed Critical Сайклон Фармасютикалс, Инк.
Publication of UA96980C2 publication Critical patent/UA96980C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200909229A 2007-02-13 2008-02-11 Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки UA96980C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90097707P 2007-02-13 2007-02-13

Publications (1)

Publication Number Publication Date
UA96980C2 true UA96980C2 (ru) 2011-12-26

Family

ID=39690681

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909229A UA96980C2 (ru) 2007-02-13 2008-02-11 Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки

Country Status (14)

Country Link
US (2) US7906486B2 (OSRAM)
EP (1) EP2120986A4 (OSRAM)
JP (1) JP2010518160A (OSRAM)
KR (1) KR20090119897A (OSRAM)
CN (1) CN101657210A (OSRAM)
AR (1) AR065338A1 (OSRAM)
AU (1) AU2008216799A1 (OSRAM)
CA (1) CA2677749A1 (OSRAM)
IL (1) IL200364A0 (OSRAM)
MX (1) MX2009008641A (OSRAM)
NZ (1) NZ579570A (OSRAM)
TW (1) TW200845958A (OSRAM)
UA (1) UA96980C2 (OSRAM)
WO (1) WO2008100458A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677749A1 (en) * 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
RU2436587C1 (ru) * 2010-10-21 2011-12-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке
CN109528202B (zh) * 2018-11-14 2021-07-16 北京大学第一医院 一种头颈部放疗诊疗系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) * 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) * 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5206220A (en) * 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1993008815A1 (en) 1991-10-28 1993-05-13 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1994020063A2 (en) 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
RU2120298C1 (ru) 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
WO1997019691A1 (en) 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith
US6060452A (en) * 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
US7173013B2 (en) * 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
RU2229892C2 (ru) 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US20050256042A1 (en) * 2003-05-09 2005-11-17 Jeffers Michael E Methods of preventing and treating alimentary mucositis
AU2005244826B2 (en) * 2004-05-14 2010-07-29 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with immunomodulator compounds
JP4874985B2 (ja) 2004-10-27 2012-02-15 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物による出血性ウイルス感染の治療又は予防
WO2006076169A2 (en) 2004-12-28 2006-07-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of genital viral infections with immunomodulator compounds
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
AU2007240946A1 (en) * 2006-04-20 2007-11-01 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
JP2010513508A (ja) 2006-12-18 2010-04-30 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎感染を処置するための併用療法
CA2677749A1 (en) * 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
RU2007118237A (ru) 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
US20110189305A1 (en) 2007-08-23 2011-08-04 Tuthill Cynthia W Treatment of lung cancer
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたｃ型肝炎の治療または予防の方法

Also Published As

Publication number Publication date
NZ579570A (en) 2012-02-24
EP2120986A4 (en) 2010-04-07
CA2677749A1 (en) 2008-08-21
KR20090119897A (ko) 2009-11-20
US20100086622A1 (en) 2010-04-08
WO2008100458A2 (en) 2008-08-21
AU2008216799A1 (en) 2008-08-21
MX2009008641A (es) 2009-09-14
EP2120986A2 (en) 2009-11-25
IL200364A0 (en) 2010-04-29
TW200845958A (en) 2008-12-01
CN101657210A (zh) 2010-02-24
JP2010518160A (ja) 2010-05-27
US7906486B2 (en) 2011-03-15
AR065338A1 (es) 2009-06-03
WO2008100458A3 (en) 2008-11-27
US20110117211A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
WO2009067397A3 (en) Treatment for solid tumors
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2009048778A3 (en) Laminins, derivatives, and compositions including same and method for their therapeutic use
ZA201101517B (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases,and uses thereof
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2010033884A3 (en) Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
UA96980C2 (ru) Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки
WO2010039920A3 (en) Boldine compounds for promoting bone growth
WO2010005585A3 (en) 4-aminoquinazoline prodrugs
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
WO2010075255A3 (en) Methods for treating or preventing cancer and neurodegenerative diseases
WO2011028799A3 (en) Ganglioside transmucosal formulations
WO2014203074A3 (en) Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
WO2010093615A3 (en) Compounds, their syntheses, compositions, and methods to treat cancer